GLP-1RA Effects on Lean Mass and Bone Health in Midlife Women

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07422987

Acronym

GLOW

Enrollment

Registered

2026-02-20

Start date

2026-02-12

Completion date

2027-06-30

Last updated

2026-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Body Composition, Estrogen Level, GLP-1, Muscle Function

Keywords

Midlife, Women's health, Dietary quality

Brief summary

This study is designed with the interest to learn on the effects of estrogen levels and how it affects body compositions and muscle function in midlife women who are taking a GLP-1RA for weight loss.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

35 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* Females * Age 35-60 year * BMI≥30 or BMI≥27 and at least one cardiometabolic risk factor (dyslipidemia, hypertension, obstructive sleep apnea, metabolic syndrome, fatty liver, PCOS) * Newly prescribed a GLP-1RA medication * English speaking * Body weight stable for the past 6 months

Exclusion criteria

* Pregnant women * Under age 35 or over age 60 * Born male * Cannot consent for themselves * Cannot read and speak in English * Type 2 diabetes * Recently discontinued a GLP-1RA medication (less than 6-months since discontinuing) * Contraindications for taking a GLP-1 RA medication (personal or family history of medullary thyroid carcinoma, personal or family history of multiple endocrine neoplasia type 2, personal history of pancreatitis, pregnancy, hypersensitivity to the drug or any component of the drug, active suicidal ideation) * Currently taking aromatase inhibitors or selective estrogen receptor modulators (SERMs)

Design outcomes

Primary

Measure	Time frame	Description
Body weight	Baseline through 6-month visit	Assess changes in body weight by measuring weight on a calibrated scale
Body composition	Baseline through 6-month visit	Assess changes in lean and fat mass and fat-free mass in kilograms by total body DXA scan
Bone mineral density (BMD)	Baseline through 6-month visit	Assess changes in bone mineral density (BMD) by completing femur DXA scans
Muscle function	Baseline through 6-month visit	Assess muscle function changes in pounds by completing Grip strength tests

Secondary

Measure	Time frame	Description
Estrogen level role in BMD changes during GLP-1RA therapy	Baseline through 6-month visit	Examine the moderating role of estrogen levels on changes in bone mineral density (BMD) during GLP-1RA therapy.
Estrogen level role in muscle function changes during GLP-1RA therapy	Baseline through 6-month visit	Examine the moderating role of estrogen levels on changes in muscle function during GLP-1RA therapy.
Diet intake	Baseline through 6-month visit	Examine changes in dietary intake including protein consumption by collecting 24-hrs diet recalls.
Diet quality	Baseline through 6-month visit	Examine changes in dietary quality by collecting 24-hrs diet recalls.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORJohanna Finkle, MD

University of Kansas Medical Center

Outcome results